Emilio Emini - Articles and news items

Pfizer logo

Pfizer’s investigational vaccine candidate bivalent rLP2086 receives U.S. Food and Drug Administration breakthrough therapy designation for potential prevention of meningococcal B disease

Industry news / 20 March 2014 / Pfizer Inc.

Pfizer intends to submit biologics license application for bivalent rLP2086 to U.S. Food and Drug Administration by mid-2014…

Pfizer logo
Pfizer logo

Pfizer’s Prevnar 13® shown to be immunogenic in older children and adolescents

Industry news, News / 12 March 2012 / Pfizer

Data from a Phase 3 study of Prevnar 13® met all study endpoints…

Pfizer logo

Pfizer receives FDA approval to extend use of Prevnar 13®

Industry news, News / 30 December 2011 / Pfizer

First pneumococcal conjugate vaccine for adults 50+ has potential to help address high incidence of pneumococcal pneumonia…

Pfizer logo

Pfizer provides U.S. regulatory update on Prevnar 13®

Industry news, News / 29 July 2011 / Pfizer

The U.S. FDA issued a 90-day extension to the action date for the Company’s sBLA for use of Prevnar 13®…

Pfizer logo

Pfizer’s Prevnar 13® meets all study endpoints in two pivotal phase 3 trials in adults aged 50 and older

Industry news, News / 9 May 2011 / Pfizer

Pfizer Inc. announced that the data from its two pivotal Phase 3 immunogenicity and safety trials of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...